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Salmonella Typhimurium DT12, isolated from a 35-day-old
infant with diarrhea, was highly resistant to ampicillin, tetracy-
cline, chloramphenicol, streptomycin, gentamycin, sul-
famethoxazole/trimethoprim,  nalidixic acid, and fluoro-
quinolones. The patient responded to antibiotic therapy with
fosfomycin. Multidrug-resistance may become prevalent in Sal-
monella infections in Japan, as shown in this first case of a
patient infected with fluoroquinolone-resistant Salmonella.
almonella enterica serovar Typhimurium (S. Typhimu-
rium) is one of the most important causative agents of
acute human Salmonella gastroenteritis. In particular, S. Typh-
imurium definitive phage type104 (DT104), which has devel-
oped multidrug resistance to ampicillin, tetracycline,
chloramphenicol, streptomycin, sulfa drugs, and other antibi-
otics, has quickly become widespread in developed countries
and drawn much attention worldwide (1–6). In European
countries, other types of Salmonella resistant to fluoroquinolo-
nes, including DT104, have been detected, and adequate treat-
ment of infected patients is now a serious issue. We isolated S.
Typhimurium DT12, highly resistant to fluoroquinolones,
from diarrhetic stools from an infant and reported the first clin-
ical infection in Japan (7). We describe our analysis of this iso-
late’s antibiotic susceptibility and drug resistance genes: three
point mutations in the region determining quinolone resistance
were identified in gyrA and parC.
Case Report
The patient was a 35-day-old infant boy with fever, diar-
rhea, and vomiting. He was born at 38 weeks, weighing 3,296
g. Hyperbilirubinemia developed at 1 week of age. He was fed
by both breast milk and formula. The family history was unre-
markable. The baby vomited on the night of September 4,
2000, and bloody diarrhea and fever >37°C developed at 3:00
a.m. the next day. His parents consulted the maternity office
where he was born, and the obstetrician prescribed oral fosfo-
mycin.  When his fever did not subside, the obstetrician
referred him to the outpatient department of pediatrics, Kansai
Medical University Kohri Hospital, Osaka, Japan. Acute
enteritis was diagnosed, and the patient was admitted to the
hospital on September 5.
On admission, the infant was 55.0 cm long and weighed
4,536 g. His temperature was 38.6°C, heart rate 162 beats/min,
respiratory rate 52/min, and blood pressure 102/palpable
mmHg. He was pale and lethargic with cold extremities and
cyanosis around the nose and mouth. His anterior fontanelle
was 1 cm in diameter without swelling. Small eruptions were
observed on his face and neck.
Laboratory evaluation was remarkable for the following:
total protein 4.9 g/dL (normal range: 5.0–6.5 g/dL), albumin
2.8 g/dL (normal range: 3.3–4.2 g/dL), C-reactive protein 2.5
mg/dL (normal: <0.3 mg/dL), leukocyte 3,730/mm3 (normal
range 5,000–19,500/mm3), neutrophils 59.4%, lymphocytes
33.0%, sodium ion 135 mEq/L (normal range: 135–147 mEq/
L), potassium ion 4.5 mEq/L (normal range: 3.6–5.0 mEq/L),
chlorine ion 108 mEq/L (normal range: 98–108 mEq/L), cal-
cium 5.0 mEq/L (normal range 4.2–5.7 mEq/L), blood urea
nitrogen 9.8 mg/dL (normal range: 4–15.4 mg/dL), creatinine
0.27 mg/dL (normal range: 0.23–0.6 mg/dL), uric acid 3.6 mg/
dL (normal range: 1.4–3.5 mg/dL), and blood sugar 93 mg/dL
(normal range: 60–100 mg/dL). S. Typhimurium DT12, named
KKH712, was isolated from his stool. Liver panel and chemis-
tries were otherwise normal.
Upon admission, fosfomycin by injection was adminis-
tered for bacterial enteritis. Frequent diarrhea and vomiting
decreased. The baby’s body temperature and C-reactive pro-
tein level normalized, and his general condition improved. He
was discharged on day 14. Outpatient follow-up showed that,
with fosfomycin, his stool culture eventually tested negative
for  Salmonella. Stool cultures from his family members
(father, mother, sister, and brother) did not show the causative
Salmonella isolate, and no member of family had diarrhea or
took antimicrobial drugs. The family did not have a pet and
had not traveled overseas recently. We did not find a route of
infection.
Conclusions
We examined the S. Typhimurium DT12 (KKH712) iso-
lated from the patient for drug susceptibility. We determined
MICs of 18 antibiotics (ampicillin, cefaclor, cefazolin, ceftazi-
dime, ceftriaxone, imipenem, streptomycin, kanamycin, genta-
mycin, amikacin, tetracycline, chloramphenicol, sulfametho-
xazole/trimethoprim, fosfomycin, nalidixic acid, levofloxacin,
ciprofloxacin, and norfloxacin) against the strain by the agar
plate dilution method provided by the National Committee for
Clinical Laboratory Standards (8). The strain, S. Typhimurium
ATCC13311, was used as a sensitive strain for the comparison,
and Escherichia coli ATCC25922 was used as the quality con-
trol reference strain. Susceptibilities of S. Typhimurium DT12
*Kansai Medical University Kohri Hospital, Osaka, Japan; and
†National Institute of Infectious Diseases, Tokyo, Japan
SDISPATCHES
256 Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003
(KKH712) to the different antibiotics are shown in Table 1.
MICs were high for ampicillin (MIC:512 µg/mL), streptomy-
cin (512 µg/mL), gentamycin (32 µg/mL), tetracycline (128
µg/mL), chloramphenicol (>128 µg/mL), sulfamethoxazole/
trimethoprim (>128 µg/mL), and nalidixic acid (>512 µg/mL),
indicating resistance to these antibiotics. The strain was highly
resistant to all three fluoroquinolones tested: levofloxacin (8
µg/mL), ciprofloxacin (8 µg/mL), and norfloxacin (16 µg/
mL).
Sequence analysis of the gyrA and parC genes was per-
formed by the method described by Giraud et al. (9). In brief,
DNA fragments of each gene were amplified in 50-µL reaction
mixture by using boiled bacterial suspension with 200 µM of
deoxynucleotide triphosphate, 1 µM of the primer pairs, Taq
buffer (QIAGEN GmbH, Hilden, Germany), and 2.5 U of Taq
DNA polymerase (QIAGEN GmbH). Polymerase chain reac-
tion was run at 93°C for 30 sec, 55°C for 30 sec, and 72°C for
1 min for 35 cycles. The DNA fragments were purified by
using MicroSpin Column S-300HR (Amersham Pharmacia
Biotech, Piscataway, NJ). Sequence was determined by the
method described by Sanger et al. (10) in an automatic DNA
sequencer (Applied Biosystem 310, Perkin-Elmer Inc., Foster
City, CA) by using primer STGYRA1 or STPARC1 for gyrA
or  parC fragments, respectively (Table 2). Nucleotide
sequences of its gyrA and parC genes were determined and
point mutations were detected: Ser83Phe (TCC→ TTC) and
Asp87Asn (GAC→ AAC) in the quinolone resistance–deter-
mining region (QRDR) of gyrA and Ser80Arg (AGC→ CGC)
in the QRDR of parC.
The World Health Organization has determined that Sal-
monella is reemerging as one of the most important infectious
diseases in the world. Drug-resistant Salmonella strains, for
which infections are increasing worldwide, are of special con-
cern (1–6). In Japan, quinolone-resistant S. Typhimurium
strains from domestic cases have been emerging since 1995
(11). The phage type of the multidrug-resistant S. Typhimu-
rium that we isolated was DT12, not DT104, the prevalent
type in developed countries (12), which suggests that the strain
in this study may differ from the prevalent ones. BlnI-digested
pulsed-field gel electrophoresis patterns were different
between S. Typhimurium DT12 KKH712 and typical Japanese
isolates of S. Typhimurium DT104 (12, data not shown),
which also supports the idea that this strain is different. Some
multiple drug-resistant S. Typhimurium DT12 strains have
been reported in Japan, but the frequency of this strain is not as
high as that of DT104 (12). Recently, other S. Typhimurium
DT12 strains with high fluoroquinolone resistance in humans
were isolated in Japan (pers. comm., H. Izumiya). However,
scant data are available on fluoroquinolone resistance of S.
Typhimurium DT12 originating from cattle in Japan.
The main mechanism of fluoroquinolone resistance by
Enterobacteriaceae, including Escherichia coli, is reported to
be several point mutations in the QRDR in the structural gene
of DNA gyrase or DNA topoisomerase IV. Analysis of the qui-
nolone resistant gene in the strain obtained from our patient
showed three point mutations in QRDR: Ser83Phe
(TCC→ TTC) and Asp87Asn (GAC→ AAC) in QRDR of gyrA
and Ser80Arg (AGC→ CGC) in QRDR of parC. These same
three mutations have been reported previously in fluoroqui-
nolone-resistant bacteria (9,13–15). However, to the best of
our knowledge, this report is the first of a Salmonella isolate
highly resistant to fluoroquinolones from a clinical case with
three point mutations in the QRDR (16).
Ampicillin, chloramphenicol, sulfa drugs, and fluoroqui-
nolone have been established as standard first-line therapy for
Salmonella infections. If the Salmonella is a multidrug-resis-
tant strain as in this case, however, all of these antibiotics will
be ineffective, and treatment will be difficult. In fact, a previ-
ous report describes a patient death after a nosocomial Salmo-
nella outbreak in a U.S. hospital (17).
Fosfomycin, administered to our patient, has been used to
treat various infectious diseases in Japan. This drug is one of
the most commonly used antibiotics in Japan because it pro-
duces relatively few side effects. In our case, fosfomycin was
quite effective against the multidrug- and fluoroquinolone-
Table 1. MICs (µg/mL) of 18 antibiotics for Salmonella Typhimurium 
strains (ATCC13311 and KKH712)
Antibiotics ATCC13311 KKH712
Ampicillin <0.5 512
Cefaclor 0.5 1
Cefazolin 1 2
Ceftazidime 0.13 0.25
Ceftriaxone <0.03 0.06
Imipenem 0.13 0.06
Streptomycin 8 512
Kanamycin 1 8
Gentamicin 0.25 32
Amikacin 0.5 1
Tetracycline 1 128
Chloramphenicol 4 >128
Sulfamethoxazole/trimethoprim 1 >128
Fosfomycin 0.5 0.5
Nalidixic acid 4 >512
Levofloxacin <0.03 8
Norfloxacin 0.06 16
Ciprofloxacin <0.03 8
Table 2. Primers for sequence analysis of gyrA and parC 
Primers Sequences
STGYRA1 5´-TGTCCGAGATGGCCTGAAGC-3´
STGYRA12 5´-CGTTGATGACTTCCGTCAG-3´
STPARC1 5´-ATGAGCGATATGGCAGAGCG-3´
STPARC2 5´-TGACCGAGTTCGCTTAACAG-3´Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 257
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resistant  Salmonella; our patient recovered after taking this
antibiotic, which is considered relatively safe. Fosfomycin is
often administered to babies and children and expected to be
effective; however, fosfomycin-resistant Salmonella has been
reported in Japan (18). In Japan, fosfomycin was approved for
use in animals in 1986. Thus far, fosfomycin-resistant Salmo-
nella has not increased. We must be very careful not to overuse
this antibiotic and thereby introduce Salmonella strains resis-
tant to fosfomycin as has happened with the fluoroquinolones.
The emergence of fluoroquinolone-resistant Salmonella in
European countries is attributed to the use of fluoroquinolones
in livestock and the accompanying natural selection of the
resistant strain. In Japan, fluoroquinolones were approved for
use in animals in 1991. Fluoroquinolones tend to be used more
frequently in Japan than in Europe. Persons in Japan, then, are
at risk of having more infectious diseases caused by fluoroqui-
nolone-resistant  Salmonella and other bacteria. Surveillance
for antimicrobial resistance of Salmonella should be contin-
ued, particularly to monitor the emergence of strains with high
fluoroquinolone resistance from humans and livestock.
Mr. Nakaya is the chief medical technologist of Clinical Center
Laboratory, Kansai Medical University Kohri Hospital, Osaka, Japan.
His research interests include detecting and controlling antimicrobial
resistance in hospitals.
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